Humanigen's Ifabotuzumab Shows Encouraging Action In Early-Stage Brain Cancer Study

  • Humanigen Inc HGEN has announced results from the Phase 1 trial evaluating its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM), the most frequent and lethal primary brain cancer.
  • The results will be presented as a poster at the AACR Annual Meeting 2021.
  • In the study, ifabotuzumab demonstrated highly sensitive, specific, and reproducible targeting of the tumor and tumor microenvironment in all patients.
  • No dose-limiting toxicities were observed, and all adverse events were readily manageable.
  • The Phase 1 study was designed to determine the safety and recommended Phase 2 dose of ifabotuzumab.
  • Ifabotuzumab is a non-fucosylated IgG1κ antibody targeting the EphA3 receptor. EphA3 is a tumor-restricted antigen expressed in the tumor vasculature and tumor stroma of various solid tumors.
  • Additional studies are planned to evaluate ifabotuzumab as an antibody-drug conjugate in solid tumor patients.
  • Price Action: HGEN shares are trading 2.8% higher at $17.4 in the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralbrain cancerBriefsPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!